Pharmacogenomic Study of Selected Genes Affecting Amlodipine Blood Pressure Response in Patients with Hypertension
Asif Jan,Abdullah Alanzi,Ramzi Mothana,Jun-Ya Kaimori,Syed Ali,Tahir Muhammad,Muhammad Saeed,Rani Akbar,Mehtab Khan
DOI: https://doi.org/10.2147/pgpm.s481068
2024-10-30
Pharmacogenomics and Personalized Medicine
Abstract:Asif Jan, 1, 2 Abdullah R Alanzi, 3 Ramzi A Mothana, 3 Jun-Ya Kaimori, 4 Syed Shaukat Ali, 5 Tahir Muhammad, 6, 7 Muhammad Saeed, 8 Rani Akbar, 9 Mehtab Khan 10 1 Department of Pharmacy, University of Peshawar, Peshawar, 25000, Pakistan; 2 District Headquarter Hospital (DHQH) Charsadda, Charsadda, 24430, Pakistan; 3 Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, 1151, Saudi Arabia; 4 Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan; 5 Department of Pharmacy, University of Malakand, Malakand, Pakistan; 6 Molecular Neuropsychiatry & Development (Mind) Lab, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, 43964, Canada; 7 Institute of Medical Science, University of Toronto, Toronto, ON, 43964, Canada; 8 Department of Pharmacy, Qurtaba University of Science and Technology, Peshawar, 25000, Pakistan; 9 Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan; 10 Department of Biology, Faculty of Science, University of Moncton, Moncton, NB, E1A 3E9, Canada Correspondence: Asif Jan, Email Introduction: Despite the availability of various antihypertensive medications, the response to these medications varies among individuals. Understanding how individual genetic variations affect drugs treatment outcomes is a key area of focus in precision medicine. This study investigated the correlation between single nucleotide polymorphisms (SNPs) in selected genes (CACNA1C, CACNA1D, ABCB1, ACE, ADBR2, and NOS1AP) and the blood pressure (BP) control by amlodipine. Methods: Four hundred individuals of Pashtun ethnicity undergoing amlodipine treatment for hypertension were included in the present study and divided into the controlled (BP less than 140/90 mmHg) and uncontrolled (BP greater than 140/90 mmHg) hypertension groups. Blood samples (3 mL) were collected from each participant, and DNA was extracted using the Kit method. Ten SNPs in amlodipine pharmacogenes were selected and genotyped using real-time PCR with the TaqMan ® system. Logistic regression model was used to determine the association between SNPs and the amlodipine BP response. Results: Notable association were observed between SNP rs2239050/CACNA1C and amlodipine blood pressure response, with GG genotype carriers demonstrating a better response (P=0.004) than individuals carrying CC or CG genotypes. SNP rs312481/CACNA1D also exhibited a positive pharmacogenetic association, Individuals with the GG genotype showing a considerable reduction in BP (P=0.021) compared to participants with AA or GA genotypes. In case of SNP rs429/ACE individuals carrying TA genotype were less likely to achieve BP control (P=0.002) than AA genotype carriers. Conclusion: Our finding suggests that the SNPs rs2239050/CACNA1C, rs312481/CACNA1D and rs429/ACE influence amlodipine blood pressure response in patients with hypertension. It is recommended that prior knowledge of amlodipine associated pharmacogenetic variants is important that could improve its treatment outcomes in hypertensive patients. Keywords: pharmacogenomics, hypertension, genetic markers, personalized medicine, amlodipine, Pashtun, Pakistan Hypertension (HTN) is a major public health issue, when left untreated leads to the development of various disorders like cardiovascular diseases, renal failure and premature death. 1 The global burden of HTN has rapidly increased over the past decades, especially in low- and middle-income countries. 2,3 According to the World Health Organization (WHO) global report on hypertension (1990–2019) the HTN prevalence and incidence among adults has increased twofold, rising from 650 million in 1990 to 1.3 billion in 2019. The surge in the number of hypertensive cases is more frequent in the South Asian and Western Pacific regions than in the European and American populations. 4,5 The prevalence of hypertension in Pakistan, a developing, middle-income south Asian nation, is alarmingly high and requires immediate medical attention. National Health Survey of Pakistan on hypertension prevalence reported that 46.2% of adult Pakistani population is affected by hypertension and this number is escalating rapidly. 6 Because of its growing mortality rate and lack of its initial sign and symptoms, it is recognized as one of the high prevalent chronic non-communicable diseases globally, earning the moniker of a "silent killer". 7 The key players contributing to high prevalence of hypertension -Abstract Truncated-
pharmacology & pharmacy